Protein kinase C (PKC) conventional and novel isoforms (cPKC and nPKC)

Protein kinase C (PKC) conventional and novel isoforms are a family of serine/threonine kinases that serve as critical nodes in signal transduction pathways. The conventional isoforms (alpha, beta I, beta II, and gamma) require both calcium and diacylglycerol (DAG) for activation, whereas the novel isoforms (delta, epsilon, eta, and theta) are activated by DAG but are independent of calcium (Newton, 2018, Chemical Reviews). These enzymes regulate a wide array of cellular functions, including proliferation, differentiation, apoptosis, and the immune response (Mochly-Rosen et al., 2012, Nature Reviews Drug Discovery). In disease states, PKC dysregulation is associated with cancer progression, diabetic microvascular complications, and inflammatory conditions (StatPearls, 2023). Pharmacological targeting of these isoforms has led to the development of inhibitors like midostaurin and ruboxistaurin, though achieving isoform specificity remains a major hurdle in drug design (PubChem). Because these kinases are involved in nearly every aspect of cell biology, their therapeutic modulation requires careful consideration of the specific isoform and tissue context to avoid significant toxicity.

Other names

Protein kinase CPKCDAG-sensitive PKCCalcium-dependent and calcium-independent PKCPRKC

Inhibition of the ATP-binding site within the catalytic domain or modulation of the regulatory domain through diacylglycerol (DAG) binding sites (C1 domains).